Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial.

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

sorafenib - Generic mfg.

http://www.ncbi.nlm.nih.gov/pubmed/42762856

Amanda Cruz; Anthony B El-Khoueiry; Bruno Sangro; Ignacio Melero; Jaclyn Neely; James J Harding; Jin Yao; Marina Tschaika; Masatoshi Kudo; Olivier Rosmorduc; Richard S Finn; Robin Kate Kelley; Ruslan Novosiadly; Thomas Yau

Sep 20, 2026